All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Samsung Bioepis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Merck, Samsung Join Newly Crowded Market for Herceptin Biosimilars

Contact the Supplier

Lead Product(s): Trastuzumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 15, 2020

Details:

ONTRUZANT is being launched in the U.S. by Merck as part of a development and commercialization agreement with Samsung Bioepis.